CNR Institutional Research Information System

SALVATORE, GIULIANA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 156
AS - Asia 48
EU - Europa 26
AF - Africa 1
SA - Sud America 1
Totale 232
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 156
SG - Singapore 38
FI - Finlandia 14
CN - Cina 10
DE - Germania 6
IT - Italia 5
EC - Ecuador 1
NL - Olanda 1
ZA - Sudafrica 1
Totale 232
Salva come PNG Salva come JPEG
Città #
Santa Clara 139
Singapore 29
Helsinki 14
Falkenstein 6
Milan 2
San Nicola Manfredi 2
Ashburn 1
Guayaquil 1
Totale 194
Salva come PNG Salva come JPEG
Nome #
Osteopontin is overexpressed in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness. 14
Multimodal imaging for a theranostic approach in a murine model of B-cell lymphoma with engineered nanoparticles 13
Generation and characterization of novel monoclonal antibodies to the Ret receptor tyrosine kinase. 12
Glial cell line-derived neurotrophic factor induces proliferative inhibition of NT2/D1 cells through RET-mediated up-regulation of the cyclin-dependent kinase inhibitor p27(kip1). 12
BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. 11
Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. 10
Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. 10
Induction of caspase-dependent programmewd cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins. 10
BRAF is a therapeutic target in aggressive thyroid carcinoma. 10
DNA Immunization follone by a single boost with cells: a protein-freeimmunization protocol for production of monoclonal antibodies against the native form of membrane proteins. 10
Pros and cons of cellular studies in developing new drugs for thyroid cancers. 9
BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas. 9
Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma. 9
Presence of BRAF V600E in very early stages of Papillary Thyroid carcinoma. 9
Mitogenic effects of the up-regulation of minichromosome maintenance proteins in anaplastic thyroid carcinoma. 9
Receptor tyrosine kinase inhibitors in thyroid cancer. 9
RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma 8
The lncRNA TEX41 is upregulated in pediatric B-Cells Acute Lymphoblastic Leukemia and it is necessary for leukemic cell growth 8
The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype. 8
TWIST1 plays a pleiotropic role in determining the anaplastic thyroid cancer phenotype. 8
Heterogeneity in the distribution of RET/PTC rearrangements within individual post-Chernobyl papillary thyroid carcinomas. 8
BAY 43-9006 inhibition of oncogenic RET mutants. 8
Only the substitution of methionine 918 with a threonine and not with other residues activates RET transforming potential 7
Molecular biology of the MEN2 gene 6
Glial cell line-Derived Neurotrophic Factor differentially stimulates Ret mutants associated with the Multiple Endocrine Neoplasia type 2 syndromes and Hirschsprung's disease 6
Different mutations of the RET gene cause different human tumoral diseases 6
Totale 239
Salva come PNG Salva come JPEG
Categoria #
all - tutte 874
article - articoli 874
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.748
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202410 0 0 0 0 0 0 0 0 0 0 10 0
2024/2025229 1 1 41 17 126 31 9 3 0 0 0 0
Totale 239